Vancouver, Canada

Leon Wan

This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Jazz Pharmaceuticals Therapeutics, Inc.. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Leon Wan. Retrieved from https://idiyas.com/inventor/leon-wan-xpdhucqy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Leon Wan: Innovator in Liposomal Formulations

Introduction

Leon Wan is a notable inventor based in Vancouver, Canada. He has made significant contributions to the field of pharmaceuticals, particularly in the development of liposomal formulations.

Latest Patents

Leon Wan holds a patent for "Liposomal formulations of Bcl inhibitors." This patent includes liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions that include such liposomes, and methods for using these formulations to treat hyperproliferative disorders. He has 1 patent to his name.

Career Highlights

Leon Wan is currently employed at Jazz Pharmaceuticals Therapeutics, Inc., where he continues to innovate in the pharmaceutical sector. His work focuses on developing advanced therapeutic solutions that can improve patient outcomes.

Collaborations

Leon collaborates with esteemed colleagues such as Paul Tardi and Shyam Madhusudan Garg, contributing to a dynamic and innovative work environment.

Conclusion

Leon Wan's contributions to liposomal formulations and his ongoing work at Jazz Pharmaceuticals Therapeutics, Inc. highlight his role as a key innovator in the pharmaceutical industry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…